ProCE Banner Activity

Overview of HIV Prevention

Text Module

Comprehensive expert review of currently available and investigational HIV prevention strategies.

Released: September 17, 2020

Expiration: September 16, 2021

No longer available for credit.

Share

Faculty

Joseph J. Eron

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Daniel R. Kuritzkes

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Sharon L. Hillier

Sharon L. Hillier, PhD

Professor and Vice Chair for Faculty Affairs
Director, Reproductive Infectious Disease Research
Department of Obstetrics, Gynecology and Reproductive Sciences
Professor
Department of Microbiology and Molecular Genetics
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead

ViiV Healthcare

Program Director Disclosure

Program Director

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, and ViiV and funds for research support from Gilead Sciences, Janssen, and ViiV. Dr. Eron disclosed in previous editions that he had received consulting fees from AbbVie, Avexa, Bristol-Myers Squibb, Chimerix, EMD Serono, Inhibitex, Kainos, Koronis, Myriad, Pfizer, Roche Molecular Systems, Tobira, Tibotec/Janssen, TRIO Health, and Virco; had received funds for research support from AbbVie, Bristol-Myers Squibb, Merck, Panacos, TaiMed, and Tobira; had served on speaker bureaus for Bristol-Myers Squibb, Gilead Sciences, Roche, Tibotec, and Virco; and had served on data and safety monitoring boards for TaiMed and Vertex.

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Gilead Sciences, GlaxoSmithKline, Merck, and ViiV and funds for research support from Gilead Sciences, GlaxoSmithKline, Janssen, Merck, and ViiV. Dr. Kuritzkes disclosed in previous editions that he had received consulting fees from Bionor, Bristol-Myers Squibb, Celera, InnaVirVax, Janssen, Oncolys, Teva, Tobira, and ViroStatics and fees for non-CME/CE services from Merck and ViiV.

Faculty Disclosure

Primary Author

Sharon L. Hillier, PhD

Professor and Vice Chair for Faculty Affairs
Director, Reproductive Infectious Disease Research
Department of Obstetrics, Gynecology and Reproductive Sciences
Professor
Department of Microbiology and Molecular Genetics
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Sharon L. Hillier, PhD, has disclosed that she has received consulting fees from Merck. Dr. Hillier disclosed in previous editions that she had served as a consultant for Bayer, Bristol-Myers Squibb, Cepheid, Johnson & Johnson, and Symbiomix and had served on the advisory board for Bayer and Merck.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.